Despite the COVID-19 pandemic, the FDA approved 47 new molecular entities in 2020, including one for ophthalmology, compared with 48 in 2019, according to a speaker at the virtual Ophthalmology Innovation Summit Year in Review meeting.
“FDA approvals were not really affected by COVID-19 since the pivotal trials were wrapping up or already wrapped up, but it will be interesting to see how 2021 approvals turn out given this utterly unique year in clinical research,” Patrick Healy, MPH, co-founder of Trial Runners, told Healio/OSN.
A high proportion of the molecular (Read more...)
Uncategorized